130 related articles for article (PubMed ID: 8456319)
1. Therapy of factor VIII deficiency.
Gill JC
Semin Thromb Hemost; 1993; 19(1):1-12. PubMed ID: 8456319
[TBL] [Abstract][Full Text] [Related]
2. [Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates].
Tavares A; Galvão M
Acta Med Port; 1992 Dec; 5(11):587-90. PubMed ID: 1293952
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in hemophilia.
Tann G
Southeast Asian J Trop Med Public Health; 1979 Jun; 10(2):218-28. PubMed ID: 524146
[TBL] [Abstract][Full Text] [Related]
4. Advances in care of children with hemophilia.
Manco-Johnson MJ; Riske B; Kasper CK
Semin Thromb Hemost; 2003 Dec; 29(6):585-94. PubMed ID: 14719175
[TBL] [Abstract][Full Text] [Related]
5. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
6. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
Mannucci PM
Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
[TBL] [Abstract][Full Text] [Related]
7. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
8. Hemophilia A--from basic science to clinical practice.
Klinge J; Ananyeva NM; Hauser CA; Saenko EL
Semin Thromb Hemost; 2002 Jun; 28(3):309-22. PubMed ID: 12098093
[TBL] [Abstract][Full Text] [Related]
9. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
Briët E; Mauser-Bunschoten EP
Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
[TBL] [Abstract][Full Text] [Related]
10. [Current status and future prospects of hemophilia treatment].
Lopaciuk S
Acta Haematol Pol; 1995; 26(2 Suppl 1):44-55. PubMed ID: 7653234
[TBL] [Abstract][Full Text] [Related]
11. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
Pollmann H
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
[TBL] [Abstract][Full Text] [Related]
12. [Current clinical aspects in hemophilia treatment].
Meili EO
Schweiz Med Wochenschr; 1989 Sep; 119(39):1332-41. PubMed ID: 2508219
[TBL] [Abstract][Full Text] [Related]
13. Hemophilia A.
Lusher JM; Warrier I
Hematol Oncol Clin North Am; 1992 Oct; 6(5):1021-33. PubMed ID: 1400070
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
15. Use of blood products and factor concentrates for coagulation therapy.
Fritsma MG
Clin Lab Sci; 2003; 16(2):115-9. PubMed ID: 12757192
[TBL] [Abstract][Full Text] [Related]
16. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetics of hemophilia A].
De Brasi CD; Slavutsky IR; Larripa IB
Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
[TBL] [Abstract][Full Text] [Related]
18. Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors.
Johnson AJ; Mathews RW; Fulton AJ
Clin Haematol; 1984 Feb; 13(1):3-15. PubMed ID: 6426834
[TBL] [Abstract][Full Text] [Related]
19. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the understanding of the molecular biology of hemophilia A: possible implications towards a more effective therapeutic regime.
Scheiflinger F; Dorner F
Wien Klin Wochenschr; 1999 Mar; 111(5):172-80. PubMed ID: 10226347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
